Greenwich LifeSciences (GLSI) Free Cash Flow (2019 - 2026)

Greenwich LifeSciences (GLSI) has 6 years of Free Cash Flow data on file, last reported at -$3.2 million in Q4 2025.

• Quarterly Free Cash Flow fell 71.4% year-over-year to -$3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$9.9 million (down 36.43% YoY) and the FY2025 annual result came in at -$9.9 million, down 36.43% from the prior year.
• Free Cash Flow eased to -$3.2 million in Q4 2025, from -$2.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$528270.0 in Q1 2021 to a low of -$3.2 million in Q4 2025.
• A 5-year average of -$1.7 million and a median of -$1.8 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 268.65% — and 2023, when it gained 20.06%.
• Tracing GLSI's Free Cash Flow over 5 years: stood at -$2.3 million in 2021, then gained by 4.16% to -$2.2 million in 2022, then gained by 0.73% to -$2.2 million in 2023, then grew by 14.02% to -$1.9 million in 2024, then sank by 71.4% to -$3.2 million in 2025.
• The last three Free Cash Flow figures came in at -$3.2 million (Q4 2025), -$2.7 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.